In this article
Boston Scientific
said on Thursday it will buy medtech firm Penumbra
in a deal valued at about $14.5 billion to expand its portfolio of cardiovascular devices, in the largest acquisition by the Massachusetts-based company in two decades.
The acquisition is the first major healthcare deal of 2026, a year analysts and industry insiders expect will bring a wave of mega-mergers as companies take advantage of a more favourable regulatory backdrop and easing interest rates to bolster their portfolios.
